Literature DB >> 15449218

The restless legs syndrome and periodic limb movement disorder: a review of management.

Suzanne Lesage1, Wayne A Hening.   

Abstract

The restless legs syndrome (RLS) and periodic limb movement disorder (PLMD) are distinguishable but overlapping disorders. Both feature nocturnal involuntary limb movements (periodic limb movements) that can cause sleep disruption, but each has distinct clinical features that are relevant to the diagnosis and management of the patient. The diagnosis of RLS is made by meeting established clinical criteria, not from discovery of periodic limb movements of sleep (PLMS) on a sleep study. PLMD, however, does require the presence of PLMS on polysomnography as well as an associated sleep complaint. Moreover, PLMS are themselves nonspecific, occurring both with RLS and with other sleep disorders as well as in normal individuals. The diagnosis of PLMD, then, requires not merely finding a significant number of PLMS but also excluding other potential causes for the associated sleep complaint. Treatment of RLS is based on consideration of the pattern and severity of the disorder, with dopaminergic drugs generally favored for initial treatment. Anticonvulsants, opioids, and sedative/hypnotics also have a role. A treatment algorithm is provided to assist with the management of RLS. Treatment of PLMD relies on many of the same medications, but is generally more straightforward and places a greater reliance on levodopa compounds and sedative-hypnotics.

Entities:  

Mesh:

Year:  2004        PMID: 15449218     DOI: 10.1055/s-2004-835066

Source DB:  PubMed          Journal:  Semin Neurol        ISSN: 0271-8235            Impact factor:   3.420


  12 in total

1.  Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment.

Authors:  Birgit Högl; Walter Paulus; Peter Clarenbach; Claudia Trenkwalder
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

2.  Topiramate-induced restless legs syndrome: a report of two cases.

Authors:  Andrea Romigi; Francesca Izzi; Fabio Placidi; Francesca Sperli; Angela Cervellino; Maria Grazia Marciani
Journal:  J Neurol       Date:  2007-08       Impact factor: 4.849

3.  Restless legs syndrome induced by topiramate: two more cases.

Authors:  Pedro Emilio Bermejo
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

4.  [Portable sleep monitoring in patients with disorders in falling asleep or maintaining sleep].

Authors:  I Fietze; K Nötzel; A Blau; M Glos; T Penzel
Journal:  Nervenarzt       Date:  2012-08       Impact factor: 1.214

5.  Epidemiology of exercise and sleep.

Authors:  Shawn D Youngstedt; Christopher E Kline
Journal:  Sleep Biol Rhythms       Date:  2006-08       Impact factor: 1.186

Review 6.  Sleep disturbances in patients with post-traumatic stress disorder: epidemiology, impact and approaches to management.

Authors:  Michael J Maher; Simon A Rego; Gregory M Asnis
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 7.  Evidence-based recommendations for the assessment and management of sleep disorders in older persons.

Authors:  Harrison G Bloom; Imran Ahmed; Cathy A Alessi; Sonia Ancoli-Israel; Daniel J Buysse; Meir H Kryger; Barbara A Phillips; Michael J Thorpy; Michael V Vitiello; Phyllis C Zee
Journal:  J Am Geriatr Soc       Date:  2009-05       Impact factor: 5.562

8.  Pramipexole in restless legs syndrome: an evidence-based review of its effectiveness on clinical outcomes.

Authors:  William Winlow
Journal:  Core Evid       Date:  2005-03-31

9.  Topiramate-induced periodic limb movement disorder in a patient affected by focal epilepsy.

Authors:  Andrea Romigi; Giuseppe Vitrani; Alfredo D'Aniello; Giancarlo Di Gennaro
Journal:  Epilepsy Behav Case Rep       Date:  2014-05-21

10.  Migraine and periodic limb movement disorders in sleep in children: a preliminary case-control study.

Authors:  Maria Esposito; Pasquale Parisi; Silvia Miano; Marco Carotenuto
Journal:  J Headache Pain       Date:  2013-07-01       Impact factor: 7.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.